Galmed Pharmaceuticals Ltd
GLMD0.664USD
+0.069+11.58%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
3.64MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Galmed Pharmaceuticals Ltd Unternehmen
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd Informationen
BörsenkürzelGLMD
Name des UnternehmensGalmed Pharmaceuticals Ltd
IPO-datumMar 13, 2014
CEOBaharaff (Allen)
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeMar 13
Addresse16 Tiomkin Street
StadtTEL AVIV-YAFO
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl6578317
Telefon97236938448
Websitehttps://www.galmedpharma.com
BörsenkürzelGLMD
IPO-datumMar 13, 2014
CEOBaharaff (Allen)
Führungskräfte von Galmed Pharmaceuticals Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+8834.00%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+6251.00%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+6251.00%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+6233.00%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+3123.00%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+3082.00%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
+3124.00%
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+8834.00%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+6251.00%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+6251.00%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+6233.00%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+3123.00%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+3082.00%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Jan 29
Aktualisiert: Thu, Jan 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
Andere
98.30%
Aktionäre
Aktionäre
Anteil
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
Andere
98.30%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
1.00%
Individual Investor
0.92%
Investment Advisor
0.05%
Andere
98.03%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
29
75.39K
1.06%
-34.77K
2025Q3
29
75.58K
1.38%
-16.12K
2025Q2
36
135.24K
2.48%
+20.85K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Citadel Advisors LLC
50.49K
0.71%
+50.49K
--
Sep 30, 2025
Baharaff (Allen)
36.94K
0.52%
+8.83K
+31.44%
Mar 21, 2025
Two Sigma Investments, LP
21.20K
0.3%
+21.20K
--
Sep 30, 2025
Nehemya (Guy)
6.28K
0.09%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.09%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.09%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.05%
+3.12K
+1148.16%
Mar 21, 2025
Sidransky (David)
3.12K
0.04%
+3.08K
+7338.10%
Mar 21, 2025
Poshinski (Amir)
3.12K
0.04%
+3.12K
--
Mar 21, 2025
UBS Financial Services, Inc.
963.00
0.01%
-5.94K
-86.05%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
